- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:46 | Alvotech - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11:42 | Alvotech, Advanz Pharma secure European approval for Gobivaz, Simponi biosimilar | 2 | Seeking Alpha | ||
| 10:30 | European Commission approves Alvotech's biosimilar golimumab | 2 | Investing.com | ||
| 10:06 | Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) | 3 | GlobeNewswire (USA) | ||
| 10:00 | Alvotech S.A.: Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) | 391 | GlobeNewswire (Europe) | Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ("Advanz Pharma"), a... ► Artikel lesen | |
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON 20.11.2025 | 91 | Xetra Newsboard | The following instruments on XETRA do have their first trading 20.11.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.11.2025
Aktien
1 SE0025011463 Alvotech SDR
2 AU0000004DS8... ► Artikel lesen | |
| ALVOTECH SDR Aktie jetzt für 0€ handeln | |||||
| 12.11. | Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update | 500 | GlobeNewswire (Europe) | Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine... ► Artikel lesen | |
| 12.11. | Alvotech - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 11.11. | Uncovering Potential: Alvotech's Earnings Preview | 13 | Benzinga.com | ||
| 10.11. | Alvotech: Britisches Gericht weist einstweilige Verfügung von Regeneron gegen Eylea-Biosimilar ab | 14 | Investing.com Deutsch | ||
| 10.11. | UK court rejects Regeneron's injunction against Alvotech's Eylea biosimilar | 4 | Investing.com | ||
| 10.11. | UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea (aflibercept) | 278 | GlobeNewswire (Europe) | REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| 07.11. | Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz | 7 | Pharmaceutical Business Review | ||
| 07.11. | Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz | 6 | Pharmaceutical Technology | ||
| 06.11. | Alvotech, Advanz Pharma Receive MHRA Marketing Authorizations for Gobivaz | 11 | Contract Pharma | ||
| 06.11. | Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz, a Biosimilar to Simponi (golimumab), from the MHRA | 277 | GlobeNewswire (Europe) | REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| 06.11. | UK regulator approves Alvotech's golimumab biosimilar for immune diseases | 4 | Investing.com | ||
| 04.11. | Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update | 9 | GlobeNewswire (USA) | ||
| 04.11. | Deutsche Bank downgrades Alvotech stock to Hold on manufacturing issues | 10 | Investing.com | ||
| 04.11. | Deutsche Bank stuft Alvotech wegen Produktionsmängeln auf "Hold" herab | 3 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
127 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,245 | +3,09 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 19,460 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| NUVATION BIO | 7,160 | 0,00 % | Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage | ||
| NUVALENT | 107,08 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 82,14 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,88 | 0,00 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| ARCUTIS BIOTHERAPEUTICS | 27,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,050 | 0,00 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| ADMA BIOLOGICS | 15,950 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,940 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 36,500 | 0,00 % | Structure Therapeutics stock rating reiterated ahead of key trial data | ||
| PRAXIS PRECISION MEDICINES | 189,82 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| BIONTECH | 88,25 | +0,34 % | BioNTech Aktie: Große Gewinne? - Bayer, Evotec, Hensoldt, Kontron und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,035 | 0,00 % | Is Recursion Pharmaceuticals a Meme Stock? | ||
| EDGEWISE THERAPEUTICS | 22,350 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen |
Das Unternehmen ALVOTECH SDR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,497 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALVOTECH SDR finden Sie auf Wallstreet Online.